The mucopolysaccharidoses (MPS) are a family of lysosomal storage diseases caused by enzyme deficiencies in the degradative pathways of glycosaminoglycans (GAGs). Because of a specific enzyme deficiency, GAGs or partially degraded GAGs accumulate in the lysosomes and may be excreted in the urine. The 4 types of MPS III (Sanfilippo syndromes A-D), characterized by the inability to degrade heparan sulfate (HS), are clinically similar, but significant phenotypic variation is observed within and among MPS III subtypes. 5 Mucopolysaccharidosis IIID (McKusick 252940) is caused by a deficiency in N-acetylglucosamine 6-sulfatase activity (G6S; EC 3.1.6.14). Clinical, biochemical, morphological, and immunohistochemical characterization of human and caprine MPS IIID has been reported. 3, 8 Heparan sulfate and N-acetylglucosamine 6-sulfate accumulate in the tissues and urine of individuals affected by MPS IIID. 8 A secondary storage of gangliosides also occurs in the central nervous system. Caprine G6S cDNA has been cloned and sequenced, 2 and the cDNA defect in caprine MPS IIID has been determined. 1 A mutation test utilizing the polymerase chain reaction (PCR) has been established for carrier detection and prenatal screening for caprine G6S deficiency. 4 Using the mutation test, 552 purebred Nubian goats (52 males and 500 females) from 20 herds in central lower Michigan (herd sizes of 1-210 goats and ages ranging from newborn to 10 years) were surveyed to determine the frequencies of the homozygous and heterozygous genotypes for MPS IIID. Efficacies of 2 DNA sampling techniques, collection of buccal epithelial cells (BECs) on cytology brushes a (a noninvasive procedure used for human PCR diagnosis 6 ) and collection of white blood cells (WBC), were also compared.
BECs were collected by swirling a cytology brush on the buccal mucosa of the lower lip. The brush was rinsed in 200 l 50 mM NaOH. Cells were lysed by boiling for 10 minutes and then neutralized with 10 l 2 M Tris-HCl, pH 8.0.
Blood was collected in ethylene diaminetetraacetic acid (EDTA) collection tubes. b WBCs were isolated by combining 100 l whole blood and 0.5 ml red cell lysis buffer (155 mM NH 4 Cl, 10 mM NaHCO 3 , 0.1 mM EDTA, pH 7.4), incubating the solution on ice for 10 minutes, centrifuging at 12,000 ϫ g for 30 seconds, and removing the supernatant. Cells were lysed as above.
The previously described G6S PCR-based mutation test 4 was used with the following minor modifications. One-microliter aliquots of the lysed cells were used as the DNA template in 20 l PCR mixtures. The amplicons produced were digested with AluI c at 37 C for at least 2 hours, and fragments were separated in a 4% agarose gel by electrophoresis (see Fig. 1 ). The reliability of caprine BEC samples was evaluated to rule out any unexpected PCR inhibitors. To initially evaluate this sampling technique, G6S mutation tests were performed using both BEC and WBC samples. Thirty of 36 (83%) BEC samples yielded results comparable to results of WBC samples. For the 6 other samples tested, bands were either faint or absent on the agarose gels. It was hypothesized that either not enough BECs were collected on the brushes or that feed contamination resulted in inhibition of the PCR diagnostic test. Efforts to eliminate this problem by selecting a cleaner area of the buccal mucosa and by swirling the cytology brush for an extended period of time (10 sec) were not successful. Survey of Nubian herds indicated 25% (67/298) of animals tested with BEC-derived DNA had to be retested using DNA from WBC because of faint or absent electrophoresis bands. For genetic analysis of large numbers of samples, isolation of DNA from BECs offers a noninvasive approach for sampling and saves time in sample preparation prior to PCR.
To evaluate the G6S genotype of the 552 Nubian goats, 254 goats were tested using DNA isolated from WBC, 224 were tested using DNA from BEC samples, and 74 were tested using DNA isolated from both WBC and BEC samples. Results indicating a homozygous genotype for the MPS IIID mutation using BEC DNA samples were confirmed by duplicate analysis using DNA from WBC.
Seven females out of the 552 Nubian goats tested were homozygous for the MPS IIID mutation. Overall, 25.2% (139/552) of the goats were heterozygous for the MPS IIID mutation and 1.3% (7/552) were homozygous for the mutation ( Table 1) .
The predicted frequencies of the heterozygous and homozygous genotype for caprine MPS IIID as estimated by the Hardy-Weinberg rule 7 are shown in Table 1 . The chisquare test results indicate that differences between observed and predicted genotypic frequencies are not significant (P Ͻ 0.05). The available pedigree information supports an autosomal recessive mode of inheritance for the G6S mutation.
Detailed characterization of the 7 MPS IIID-affected goats is now underway to assess the phenotypic expression of this inherited neurologic disease. Preliminary comparisons of the physical characteristics of these goats indicate that they are less severely affected than the goat with the first reported case of caprine MPS IIID. 8 The fact that some of these animals appear normal underscores the value of the PCR-based mutation test. These investigations also show that application of the test, using DNA from either BECs or WBC for Figure 1 . PCR-based assay for identification of the caprine MPS IIID mutation. A 96-bp amplicon containing the mutation site of the G6S gene was produced using caprine genomic DNA from WBC or BEC samples. The amplicons were subsequently digested with the restriction enzyme AluI and separated on a 4% agarose gel by electrophoresis. Because the mutation introduces an AluI site, the amplicon from affected animals is cut to 66 bp. Normal animals will have only the 96-bp band and heterozygous animals will have both the 96-and 66-bp bands. Extra bands are either primer dimers or the 30-bp fragment from the digestion of the amplicon with the mutation. N ϭ normal; C ϭ carrier; A ϭ affected; B ϭ blank (negative control with no DNA); M ϭ molecular weight marker V. d heterozygote detection, will facilitate a rational breeding program to restrict the incidence of caprine MPS IIID. Acknowledgements. We thank Julie Horvath, Jan Kelley, Pattie Lynch, and Jack Truscott for their assistance with the collection of the samples, the animal owners for the opportunity to collect samples, and Stacey Kraemer for reviewing the manuscript. This work was supported by NIH grant NS 16886 and by Children's Medical Research Foundation funds (MZJ). 
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Distribution of antibody titers to bovine viral diarrhea virus in infected, exposed, and uninfected beef cattle
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Bovine viral diarrhea virus (BVDV) is the leading infectious cause of abortions, stillbirths, and weak calves in Wyoming beef herds. 8 In 1995, tissues from 237 bovine fetuses and weak calves were submitted to the Wyoming State Veterinary Laboratory. From 74 cases for which a diagnosis was determined, 16 isolates of noncytopathic BVDV were identified. Diagnosis of BVDV infection in individual animals is based on virus isolation (VI), detection of viral RNA by hybridization using oligonucleotide probes or reverse transcriptase-polymerase chain reaction (RT-PCR), and demonstration of viral antigen in tissues by immunocytochemical or fluorescent antibody staining. 2, 6, 7 Diagnosis of BVDV infection in beef herds is more problematic. Herds may be screened for viremic cattle by cell-based enzyme-linked immunosorbent assay (ELISA), antigen capture ELISA, or RT-PCR with individual blood samples. 2 However, persistently infected (PI) cattle usually represent Ͻ1.0% of the herd population and are prone to early death or removal. Cows in herds experiencing infertility, abortions, or neonatal calf mortality may have experienced exposure at a considerably earlier time and at other premises, e.g., sales barns, prior to the recognition of disease. Therefore, viremic animals may no longer be detected at the time of sampling in herds where BVDV is responsible for reproductive disease.
Serum neutralization (SN) titers of cows with a history of abortion are of limited value in the diagnosis of BVDVassociated reproductive losses because the viral infection usually has occurred weeks or months prior to abortion and testing. 1 The SN titers are elevated by the time blood samples are drawn, and differences cannot be discerned between acute and convalescent samples. In many beef herds, cows and heifers are immunized multiple times with both modified live virus (MLV) and inactivated BVDV vaccines, and the majority of vaccinated cattle have antibody titers Received for publication March 3, 1997. to BVDV. The purpose of this study was to determine whether SN titers could be used to distinguish between herds naturally infected with BVDV and herds that have received multiple immunizations with MLV BVDV vaccines. Three commercial beef herds (A, B, C) were examined. Vaccination histories were obtained by interviewing the manager or owner. Blood samples were collected from all animals in herds A, B, and C and tested for viremia by an immunoperoxidase cell-based ELISA. Animals that were positive for BVDV in 2 blood samples taken 4 weeks apart were considered PI animals. In herd A, Pl animals were not detected, and BVDV-associated disease was not diagnosed from 1994 through 1996. BVDV infection in herd B was first discovered in 1993 following immunization with a MLV BVDV vaccine containing a cytopathic strain of BVDV. Several calves died, BVDV was isolated from dead calves, and a diagnosis of vaccine-induced mucosal disease was made. In 1994, 2 Pl animals were identified and removed from herd B. The endogenous virus from this herd was determined to be genotype 1 (J. Ridpath, personal communication). Herd C grazed on common pasture with herd B July-September for several years including the time period (1994) (1995) (1996) of this study. Viremic animals were not detected during 2 successive years.
In herds A and B, yearling heifers received 2 immunizations with vaccine containing genotype 1 MLV BVDV prior to breeding. All replacement heifers originated from each respective herd. All cows were vaccinated with a MLV BVDV vaccine at branding in the spring prior to being turned out with the bulls and were immunized with an inactivated BVDV vaccine in the fall. Calves from herds A and B were vaccinated with an inactivated BVDV vaccine at branding. Cows and calves in herd C did not receive any BVDV vaccines.
Blood was collected from the jugular vein of each animal into tubes containing heparin. a In herds A and B, blood collection occurred at the time of vaccination of calves at weaning. Herd C is unvaccinated, and blood samples were collected from calves and cows in February 1996. Plasma
